Coverage of Medications That Treat Opioid Use Disorder and Opioids for Pain Management in Marketplace Plans, 2017
| Autor: | Lauren Riedel, Haiden A. Huskamp, Alisa B. Busch, Colleen L. Barry |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
MEDLINE 01 natural sciences Article Health Services Accessibility Insurance Coverage 03 medical and health sciences 0302 clinical medicine Health Insurance Exchanges Opiate Substitution Treatment medicine Humans 030212 general & internal medicine 0101 mathematics Intensive care medicine Extramural business.industry Opioid use 010102 general mathematics Public Health Environmental and Occupational Health Opioid use disorder Pain management Insurance Pharmaceutical Services Opioid-Related Disorders medicine.disease Substance abuse Buprenorphine Naloxone Drug Combination business Insurance coverage Buprenorphine medicine.drug |
| Zdroj: | Medical Care. 56:505-509 |
| ISSN: | 0025-7079 |
| Popis: | BACKGROUND: Efficacious medications to treat opioid use disorders (OUDs) have been slow to diffuse into practice, and insurance coverage limits may be one important barrier. OBJECTIVES: To compare coverage for medications used to treat OUDs and opioids commonly prescribed for pain management in plans offered on the 2017 Health Insurance Marketplace exchanges. RESEARCH DESIGN: We identified a sample of 100 plans offered in urban and in rural counties on the 2017 Marketplaces, weighting by population. We accessed publicly-available plan coverage information on healthcare.gov for states with a federally-facilitated exchange, the state exchange website for state-based exchanges, and insurer websites. RESULTS: About fourteen percent of plans do not cover any formulations of buprenorphine/naloxone. Plans were more likely to require prior authorization for any of the covered office-based buprenorphine or naltrexone formulations preferred for maintenance OUD treatment (i.e., buprenorphine/naloxone, buprenorphine implants, injectable long-acting naltrexone) than of short-acting opioid pain medications(63.6% vs 19.4%, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|